Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. cases per 100,000 people in 2018. “In The vaccine targets six different serotypes of borrelia bacteria.

Vaccines 119

Vaccines 119

pharmaphorum

DECEMBER 14, 2022

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ‘brake’ that protects the cancer.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

JUNE 29, 2022

The Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted GlaxoSmithKline’s (GSK) regulatory application for recombinant, adjuvanted Zoster vaccine, Shingrix, for preventing shingles (herpes zoster) in at-risk adults of the age 18 years and above.

Vaccines 64

Vaccines Immunization 64

STAT

JUNE 4, 2023

The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual road show to Boston, complete with entrepreneurial boot camps, beer-flowing receptions, and four days of nonstop networking.

Vaccines 98

Vaccines 98

STAT

OCTOBER 5, 2022

Scientists rely on gene synthesis technologies as a research tool for everything from basic research to vaccine development and drug target identification. Ever since the inception of gene synthesis, there have been concerns about possible misuse of synthetic genes. Read the rest…

Vaccines 97

Vaccines 97

pharmaphorum

AUGUST 16, 2022

One of the unexpected consequences of the COVID-19 vaccine race was that some top-tier vaccine companies like Merck, GSK and Sanofi ended up trailing the field, as their efforts to bring shots based on conventional technologies to patients were outstripped and outclassed by mRNA competitors from Pfizer/BioNTech and Moderna.

Vaccines 98

Vaccines Packaging 98

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111

Vaccines Immunization 111

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

Vaccines 111

Vaccines Immunization FDA 111

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc. and OriCiro Genomics K.K.

Vaccines 97

Vaccines Immunization 97

Pharmaceutical Technology

MAY 30, 2023

Valneva has submitted a regulatory application to Health Canada, seeking marketing approval for its chikungunya vaccine candidate, VLA1553. The vaccine is designed to be administered as a single shot and is intended for individuals aged 18 years and older. Valneva plans to make further regulatory submissions.

Vaccines 52

Vaccines FDA 52

Fierce Pharma

SEPTEMBER 5, 2023

After jumping into the mRNA game back in 2018, CanSino has built a facility in Shanghai that can produce up to 200 million vaccine doses a year, the company’s co-founder and CEO Xuefeng Yu told Reuters in a recent interview.

Vaccines 72

Vaccines 72

European Pharmaceutical Review

OCTOBER 27, 2022

Since 2018, employment numbers in the industry have grown by 11 percent, totalling $2.9 For instance, small and mid-sized biotech companies invested heavily in developing vaccines. The investigation identified that in the pandemic, the economy reduced 1.5 percent of its workforce. trillion dollars in 2021. Sluggish economic growth.

Vaccines 105

Vaccines Compounding 105

Pharmacy Is Right For Me

AUGUST 10, 2022

Dr. Brown is the National Field Director for Janssen Infectious Diseases & Vaccines. From 2015 through Jan 2018, I served as the U.S. We’re in the process of hiring a new Medical Science Liaison vaccines team that will focus on providing medical information about our vaccines portfolio, driving innovation.

Vaccines 130

Vaccines Pharmaceutical Companies Pharmaceutical Companies 130

The Checkup by Singlecare

JUNE 7, 2024

Millions of people have already received at least one dose of this shingles vaccine—but does it actually work? vaccine efficacy in preventing postherpetic neuralgia (PHN) for adults over 50, and 88.8% RELATED: Getting the Shingrix vaccine—is it worth it? vaccine effectiveness in adults over 70. For most people, yes.

Immunization 96

Immunization Vaccines Dosage FDA 96

pharmaphorum

FEBRUARY 10, 2022

It provides members with primary and preventive care, ongoing support for chronic conditions, and referrals to secondary and tertiary care, as well as prescription medicine services – the latter a result of its 2018 acquisition of PillPack. million employees – was shut down last year.

Vaccines 104

Vaccines 104

pharmaphorum

OCTOBER 26, 2021

It exited a consumer healthcare joint venture with GlaxoSmithKline in 2018, and within the last decade also sold off its vaccines division to GSK, its animal health unit to Eli Lilly and a blood diagnostics business to Grifols.

Generic Medicine 116

Generic Medicine Vaccines 116

Pharmafile

MARCH 15, 2023

This funding marks the third grant awarded from the Bill & Melinda Gates Foundation to DelSiTech since 2018. This funding marks the third grant awarded from the Bill & Melinda Gates Foundation to DelSiTech since 2018. read more

Vaccines 40

Vaccines 40

STAT

FEBRUARY 13, 2023

Reed, who joined the drugmaker in 2018 from Roche, will be leaving “to pursue a new opportunity outside Sanofi,” according to a company statement. Sanofi’s R&D activity was criticized after falling behind other suppliers in the race for a Covid-19 vaccine. Continue to STAT+ to read the full story…

Vaccines 92

Vaccines 92

pharmaphorum

FEBRUARY 3, 2021

billion in 2018, according to the latest BioIndustry Association (BIA) and Clarivate report, and represents a 1,000% increase on 2012. BIA points to a sharp dip in the number of new biotechs formed in 2020 – just eight compared to 30 in 2019 and 47 in 2018 – suggesting that the pandemic had a dramatic impact on entrepreneurship.

Vaccines 111

Vaccines 111

pharmaphorum

JULY 23, 2021

GSK chairman Sir Jonathan Symonds highlighted McNamara’s experience in integrating businesses on two prior occasions – combining Novartis and GSK’s consumer health businesses and overseeing the creation of the JV with Pfizer in 2018 – as evidence that he is the best candidate to be chief executive of the demerged company.

Vaccines 111

Vaccines 111

Pharmaceutical Technology

JUNE 27, 2022

As such, a hepatitis C vaccine may yet be needed for elimination, since there are cohorts of patients who will not be reached, Foster said during the subsequent panel discussion. Guidelines released in 2018 advised hepatitis C treatment from the age of 12. Based on WHO’s 2018 data, 3.26

Vaccines 105

Vaccines 105

pharmaphorum

MARCH 1, 2021

AstraZeneca has sold its stake in Moderna for more than $1 billion as the US biotech’s shares soared in value following its coronavirus vaccine breakthrough. Moderna was among the first companies to get a COVID-19 vaccine approved and has been selling it at a profit, even though the project was kick-started with around $1.5

Vaccines 64

Vaccines 64

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Vaccines 116

Vaccines Immunization Hospitals 116

pharmaphorum

JUNE 29, 2021

Sanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year in R&D funding to an effort that it hopes will deliver at least six clinical-stage candidates by 2025. . billion, including $450 million of milestones from the original 2018 agreement.

Vaccines 52

Vaccines 52

pharmaphorum

MARCH 9, 2021

SARS-CoV-2 is likely to stay endemic in the human population for the foreseeable future, ExeVir noted, with variants capable of evading immunity the most likely cause of the disease in the future as global vaccination programmes begin to take effect. ExeVir is not the first company to spin out of VIB to focus on camelid antibodies.

Immunization 98

Immunization Vaccines FDA 98

pharmaphorum

APRIL 13, 2022

The decision to beef up its haematology pipeline comes after a setback in GSK’s late-stage pipeline involving its RSV vaccine , which has run into trouble in phase 3 trials involving pregnant women. Sierra acquired momelotinib from Gilead Sciences in 2018 after equivocal results in earlier phase 3 myelofibrosis studies.

Vaccines 105

Vaccines 105

pharmaphorum

AUGUST 3, 2021

Sanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together in 2018, and has now gone all in, offering $3.2 billion to buy the company outright. billion in potential milestones. The German government also has a sizeable stake in CureVac, which could complicate a takeover bid.

Vaccines 59

Vaccines 59

pharmaphorum

AUGUST 25, 2022

It exited a consumer healthcare joint venture with GlaxoSmithKline in 2018, and within the last decade also sold off its vaccines division to GSK, its animal health unit to Eli Lilly and a blood diagnostics business to Grifols.

Compounding 105

Compounding Vaccines 105

STAT

OCTOBER 27, 2022

The investigation began in February and covers 2017, 2018, and 2019. The Italian branch allegedly sent the capital to foreign affiliates linked to a units based in Delaware called Pfizer Production and Pfizer Manufacturing. Continue to STAT+ to read the full story…

Packaging 95

Packaging FDA Vaccines 95

pharmaphorum

NOVEMBER 4, 2022

BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19 – a novel combination approach to help protect individuals against two severe respiratory viral diseases in one dose.

Vaccines 52

Vaccines Immunization FDA Pharmaceutical Companies 52

pharmaphorum

MARCH 26, 2021

Although Irvine Scientific joined parent company Fujifilm in 2018, its roots can be traced back to the 1970s, where it started life as a bovine and animal serum processing company. The post Culture changes – FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company appeared first on.

Vaccines 40

Vaccines 40

Fuld

APRIL 15, 2021

2018 — Haven, PillPack, and Aiva. Amazon’s public charge into the US healthcare market started in 2018. Then, if they needed in-person attention, Care would send a mobile nurse to the member to provide at-home administration of physical assessment, vaccines, and diagnostics tests. . Amazon’s 3 Year Moves into the U.S.

Health and Personal Care Stores 96

Health and Personal Care Stores Cerner Packaging Customer Service 96

pharmaphorum

APRIL 21, 2022

Overall spending on medicines rose 12% in 2021 to $407 billion, driven by a $29 billion spend on COVID-19 vaccines and medicines. Patient out-of-pocket (OOP) costs in aggregate rose $4 billion, or 5.3%, in 2021 to a total of $79 billion, back to the high watermark level seen in 2018 after two years of declining costs.

Vaccines 52

Vaccines 52

pharmaphorum

FEBRUARY 26, 2021

Since joining McCann Health in February 2018 , the company said Carucci has been a fixture across nearly all aspects of the business, driving scientific and medical excellence through an expanded and invigorated scientific community. ” The post McCann Health promotes Dan Carucci to global chief medical officer appeared first on.

Communication 59

Communication Vaccines 59

European Pharmaceutical Review

OCTOBER 24, 2022

This had increased by 25 days since 2018, which dropped the UK to 7 th place amongst comparator countries. As a result of this, and growing commercial pressures, pharmaceutical companies are increasingly looking elsewhere when choosing where to develop and launch new medicines and vaccines”.

Pharmaceutical Companies 91

Pharmaceutical Companies Pharmaceutical Companies Patient Care Vaccines 91

pharmaphorum

MAY 18, 2021

The split was announced in 2018 after GSK struck a deal with Pfizer to create a £10 billion joint venture. Scheduled to complete in mid-2022 the new GSK will be focused on pharmaceuticals and vaccines. The post Elliott Management could force out GSK CEO Walmsley, investor warns appeared first on.

Vaccines 59

Vaccines 59